Camrelizumab
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | DRUG-CAMRELIZUMAB |
|---|---|
| Тип | Препарат |
| Синоніми | AiRuiKaSHR-1210Камрелізумаб |
| Статус | переглянуто 2026-07-11 | очікує клінічного підпису |
| Хвороби | DIS-NPC |
| Джерела | SRC-CAPTAIN-1ST-YANG-2021 |
Дані про препарат
| Клас | Anti-PD-1 humanized IgG4 monoclonal antibody (immune checkpoint inhibitor) |
|---|---|
| Механізм дії | Humanized IgG4 monoclonal antibody binding PD-1 on activated T cells, blocking PD-1/PD-L1 and PD-1/PD-L2 interactions and restoring cytotoxic T-cell antitumor activity. Same general anti-PD-1 mechanistic class as pembrolizumab, nivolumab, and toripalimab. Studied specifically in recurrent/metastatic nasopharyngeal carcinoma (CAPTAIN-1st) combined with gemcitabine + cisplatin, as well as in multiple other Chinese-registered indications (hepatocellular carcinoma, NSCLC, esophageal SCC, classical Hodgkin lymphoma). |
| Типове дозування | Per the CAPTAIN-1st trial protocol: camrelizumab 200 mg IV every 3 weeks, combined with gemcitabine + cisplatin (GP) for up to 6 cycles, followed by camrelizumab monotherapy (200 mg IV q3w) until disease progression, unacceptable toxicity, or up to 2 years total. STUB — dosing drafted from trial-protocol recall; pending Clinical Co-Lead confirmation against the primary source. |
| Зареєстровано в Україні | False |
| Відшкодовується НСЗУ | False |
Нотатки
STUB — draft entity pending Clinical Co-Lead sign-off (CHARTER §6.1; currently dev-mode-exempted). Anti-PD-1 backbone alternative for NPC metastatic 1L combination per CAPTAIN-1st (Yang Y et al., Lancet Oncol 2021): camrelizumab + gemcitabine + cisplatin significantly improved PFS vs chemo alone in treatment-naive recurrent/metastatic NPC. NOT FDA-approved (China/NMPA-approved only) — distinguishes it from toripalimab (DRUG-TORIPALIMAB), the FDA-approved alternative for the identical clinical scenario. Reuse this entity rather than duplicate. RCCEP is a genuinely distinctive camrelizumab-class AE not shared with pembrolizumab/nivolumab/toripalimab — worth flagging for patient counseling.
Де використовується
Regimens
REG-NPC-GC-CAMRELIZUMAB- Camrelizumab + gemcitabine + cisplatin (CAPTAIN-1st) — 1L recurrent/metastatic nasopharyn...
Препарат
DRUG-TORIPALIMAB- Toripalimab